MARKET

UTHR

UTHR

Utd Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

179.12
-1.37
-0.76%
After Hours: 179.12 0 0.00% 16:19 06/11 EDT
OPEN
181.05
PREV CLOSE
180.49
HIGH
181.35
LOW
177.07
VOLUME
345.60K
TURNOVER
--
52 WEEK HIGH
212.62
52 WEEK LOW
98.37
MARKET CAP
8.02B
P/E (TTM)
19.80
1D
5D
1M
3M
1Y
5Y
Liquidia trades lower as legal battle with United Therapeutics widens
Photo by utah778/iStock via Getty Images Liquidia Corporation ([[LQDA]] -2.8%) has dropped in morning hours after United Therapeutics ([[UTHR]] +0.5%) announced that it is pursuing additional claims of trade secret
Seekingalpha · 5d ago
United Therapeutics Pursues Additional Claims For Trade Secret Misappropriation Against Liquidia And A Former United Employee; Claims Allege Liquidia 'conspired with the former employee to misappropriate United Therapeutics' trade secrets'
United Therapeutics Corporation (NASDAQ:UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc. ((a subsidiary of Liquidia Corporation,
Benzinga · 5d ago
Why Is United Therapeutics (UTHR) Down 8.8% Since Last Earnings Report?
Zacks.com · 06/04 15:31
United Therapeutics (UTHR) Begins TETON Study on Tyvaso in IPF
United Therapeutics (UTHR) enrolls the first patient in the phase III TETON study evaluating Tyvaso for treating adult patients with idiopathic pulmonary fibrosis.
Zacks · 06/04 12:06
Enrollment underway in United Therapeutics' Phase 3 Tyvaso study in idiopathic pulmonary fibrosis
The first patient has been enrolled in United Therapeutics' (UTHR) phase 3 TETON study, which is expected to evaluate approx. 396 adult patients with idiopathic pulmonary fibrosis ((IPF)).This 52-week study
Seekingalpha · 06/03 11:06
BRIEF-United Therapeutics Announces First Patient Enrolled In Phase 3 Teton Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis
reuters.com · 06/03 10:18
United Therapeutics Enrolls First Patient in Phase 3 Trial of Tyvaso in Lung Disease
MT Newswires · 06/03 06:45
Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder
Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH). The FD...
GlobeNewswire · 06/02 13:27
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of UTHR. Analyze the recent business situations of Utd Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average UTHR stock price target is 214.56 with a high estimate of 276.00 and a low estimate of 122.00.
EPS
Institutional Holdings
Institutions: 585
Institutional Holdings: 46.80M
% Owned: 104.48%
Shares Outstanding: 44.80M
TypeInstitutionsShares
Increased
111
2.76M
New
71
1.34M
Decreased
147
3.63M
Sold Out
32
475.76K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Chief Executive Officer/Director
Martine Rothblatt
President/Chief Operating Officer
Michael Benkowitz
Non-Executive Vice Chairman/Lead Director/Independent Director
Christopher Patusky
Chief Financial Officer/Treasurer
James Edgemond
Executive Vice President/General Counsel/Secretary
Paul Mahon
Independent Director
Christopher Causey
Independent Director
Raymond Dwek
Independent Director
Richard Giltner
Independent Director
Katherine Klein
Independent Director
Raymond Kurzweil
Independent Director
Linda Maxwell
Independent Director
Nilda Mesa
Independent Director
Judy Olian
Independent Director
Louis Sullivan
Independent Director
Tommy Thompson
No Data
About UTHR
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Webull offers kinds of United Therapeutics Corporation stock information, including NASDAQ:UTHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UTHR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading UTHR stock methods without spending real money on the virtual paper trading platform.